دورية أكاديمية
TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies.
| العنوان: | TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies. |
|---|---|
| المؤلفون: | Naimi A; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran., Movassaghpour AA; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Hagh MF; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Talebi M; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Entezari A; Department of Clinical Biochemistry, Division of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Jadidi-Niaragh F; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Solali S; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: ssolali@gmail.com. |
| المصدر: | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2018 Feb; Vol. 98, pp. 566-576. Date of Electronic Publication: 2017 Dec 27. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 8213295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1950-6007 (Electronic) Linking ISSN: 07533322 NLM ISO Abbreviation: Biomed Pharmacother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Paris : Editions Scientifiques Elsevier Original Publication: New York, N.Y. : Masson Pub. USA, Inc., c1982- |
| مواضيع طبية MeSH: | Antineoplastic Agents/*pharmacology , Antineoplastic Agents/*therapeutic use , Apoptosis/*drug effects , Hematologic Neoplasms/*drug therapy , TNF-Related Apoptosis-Inducing Ligand/*metabolism, Animals ; Clinical Trials, Phase II as Topic ; Hematologic Neoplasms/metabolism ; Humans |
| مستخلص: | Despite numerous attempts to find the treatment strategies that can selectively target the cancer cells, cancer still remains a major public health problem. Conventional cancer treatments such as chemo- and radio-therapies are associated with systemic toxicity and the risk of recurrence. Additionally, acquired or pre-existing resistance is the main problem of most therapies. TNF-related apoptosis-inducing ligand (TRAIL), a member of TNF superfamily, has significantly attracted the researchers to use it as an effective treatment strategy for cancer since it can preferentially induce apoptosis in a variety of primary tumor cells without affecting the adjacent normal cells. Recently, recombinant forms of TRAIL and the multiple agonists of its receptor have been evaluated in many cell lines and phase II clinical trials. Hence, we have tried to summarize the TRAIL-related therapies as a potential therapeutic option in hematological malignancies. (Copyright © 2017 Elsevier Masson SAS. All rights reserved.) |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (TNF-Related Apoptosis-Inducing Ligand) |
| تواريخ الأحداث: | Date Created: 20171231 Date Completed: 20180813 Latest Revision: 20180813 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.biopha.2017.12.082 |
| PMID: | 29288972 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1950-6007 |
|---|---|
| DOI: | 10.1016/j.biopha.2017.12.082 |